A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512
Active Not Recruiting
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/01/2025
Locations: Texas Diabetes & Endocrinology, P.A., Austin, Texas +27 locations
Conditions: Obesity, Overweight
Register for Updates
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
NCT06901349
Active Not Recruiting
The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/23/2025
Locations: Velocity Clinical Research, Dallas, Dallas, Texas +2 locations
Conditions: Obesity, Overweight
Register for Updates
Tirzepatide for Obesity and Meth Use Disorder
NCT06745128
Active Not Recruiting
This is an open-label pilot study to evaluate the feasibility and preliminary efficacy of using tirzepatide when prescribed for its United States (US) Food and Drug Administration (FDA)-approved weight-related indication in individuals with comorbid methamphetamine use disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/10/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Obesity, Methamphetamine Use Disorder
Register for Updates
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
NCT06326060
Completed
This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 42 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: Velocity Clinical Res-Dallas, Dallas, Texas +3 locations
Conditions: Obesity
Register for Updates
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
NCT06037252
Active Not Recruiting
The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/26/2025
Locations: Juno Research, Houston, Texas +1 locations
Conditions: Type 2 Diabetes, Obesity
Register for Updates
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
NCT06131437
Active Not Recruiting
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Amarillo Med Spec LLP, Amarillo, Texas +6 locations
Conditions: Obesity
Register for Updates
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383
Active Not Recruiting
The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Headlands Horizons LLC, Brownsville, Texas +3 locations
Conditions: Obesity
Register for Updates
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06047548
Active Not Recruiting
The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: The University of Texas Health Science Center at Houston, Bellaire, Texas +4 locations
Conditions: Overweight, Obesity
Register for Updates
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
NCT05433584
Active Not Recruiting
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Dallas Diabetes Research Center, Dallas, Texas
Conditions: Type 2 Diabetes
Register for Updates
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea
NCT05412004
Completed
The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with moderate to severe obstructive sleep apnea and obesity who are both unwilling or unable to use Positive Airway Pressure (PAP) therapy in GPI1 and those who are and plan to stay on PAP therapy in GPI2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2025
Locations: FutureSearch Trials of Neurology, Austin, Texas +4 locations
Conditions: Obesity, Obstructive Sleep Apnea
Register for Updates
Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over
NCT06515418
Terminated
This study aims to find out how well a combination of oral azelaprag taken once a day (QD) or twice a day (BID), along with a weekly injection of tirzepatide, works for weight management in adults 55 years and older. The researchers are also looking at safety. Estimated Study Length: * with the optional prescreening, the study duration may be up to 48 weeks. * the treatment duration will be 24 weeks followed by 12 weeks follow-up. * the visit frequency will be every 2 weeks for the first 8 wee... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
03/11/2025
Locations: Site 102, Dallas, Texas
Conditions: Obesity
Register for Updates
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
NCT05260021
Completed
The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both. The overall study will last about 60 weeks with up to 14 clinic visits and 6 phone visits. Clinic visits will include blood sample collection, physical exam and questionnaire.
Gender:
ALL
Ages:
Between 10 years and 18 years
Trial Updated:
02/24/2025
Locations: Consano Clinical Research, LLC, Shavano Park, Texas
Conditions: Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
Register for Updates